biotech
Will the FDA Oncologic Drugs Advisory Committee (ODAC) vote UNfavorably (majority against clinical benefit) on RP1 (vusolimogene oderparepvec) + nivolumab for advanced melanoma? (~July 28 2026)
EHIQ
70%
Market
—
Divergence
—
The why is Premium
The full stated basis, the stamped fact-check, what the market may be mispricing, what changed since the call opened, and what would strengthen or break the thesis — that depth is the Premium tier ($249/month).
This week's public showcase: prez 2028 ossoff →
The numbers above are always free — comprehension is never gated. The divergence is a difference of opinion, not a trade recommendation.